(NASDAQ: SLS) Sellas Life Sciences Group's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.75%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.69%.
Sellas Life Sciences Group's revenue in 2026 is $0.On average, 3 Wall Street analysts forecast SLS's revenue for 2026 to be $4,073,555,273, with the lowest SLS revenue forecast at $3,952,448,067, and the highest SLS revenue forecast at $4,234,845,515. On average, 2 Wall Street analysts forecast SLS's revenue for 2027 to be $9,975,996,781, with the lowest SLS revenue forecast at $9,679,646,890, and the highest SLS revenue forecast at $10,371,129,968.
In 2028, SLS is forecast to generate $22,930,375,071 in revenue, with the lowest revenue forecast at $22,249,495,850 and the highest revenue forecast at $23,840,074,358.